OncoMatch/Clinical Trials/NCT06952010
A Study of XB628 in Participants With Recurrent Advanced or Metastatic Solid Tumors
Is NCT06952010 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies XB628 for solid tumor.
Treatment: XB628 — This is a phase 1, first-in-human, open-label, dose-escalation study of XB628, a first-in-class bispecific antibody natural killer (NK) cell engager that targets NK group 2 member A (NKG2A), an inhibitory receptor on NK cells, and programmed cell death-ligand 1 (PD-L1).
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Disease stage
Metastatic disease required
Have a recurrent advanced or metastatic solid tumor that is histologically or cytologically confirmed. Not amenable to curative treatment with surgery or radiation.
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: systemic anticancer therapy — recurrent or metastatic
Received at least 1 line of prior systemic anticancer therapy in the recurrent or metastatic setting.
Cannot have received: NK cell-targeting therapy (monalizumab)
Received prior therapy targeting NK cells (eg, monalizumab).
Lab requirements
Blood counts
Kidney function
Liver function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Exelixis Site #5 · San Francisco, California
- Exelixis Site #4 · New Haven, Connecticut
- Exelixis Clinical Site #8 · Tampa, Florida
- Exelixis Clinical Site #10 · Boston, Massachusetts
- Exelixis Site #6 · St Louis, Missouri
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify